Acute lymphoblastic leukemia with t(1;11)(p32;q23) in a patient treated for osteogenic sarcoma.
Pinto
L I
LI
Marczyk
F F
FF
Brunetto
A L
AL
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002871:Chromosome Banding; D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1; D002880:Chromosomes, Human, Pair 11; D002945:Cisplatin / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007621:Karyotyping; D008727:Methotrexate / Q000008:administration & dosage; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced* / Q000188:drug therapy / Q000235:genetics*; D011239:Prednisolone / Q000008:administration & dosage; D014178:Translocation, Genetic; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D011239:Prednisolone; D001215:Asparaginase; D002945:Cisplatin; D008727:Methotrexate; D003630:Daunorubicin